Copyright © 2001 by the European Society of Cardiology.
Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy
Department of Cardiology, "G.M.Lancisi" Ancona, Italy
revised February 12, 2001; accepted February 15, 2001
Abstract
Background There is evidence that trimetazidine, an antiischaemic agent with a direct cytoprotective effect on the myocardium, is effective in stable angina. However, it is not clear whether trimetazidine can improve the mechanical efficiency of chronically dysfunctional myocardium, and whether this potentially beneficial effect can translate into improvements in left ventricular function as well as functional capacity.
Methods Thirty-eight patients (52·7±8 years) with post-necrotic left ventricular dysfunction (ejection fraction: 33±5%) and multivessel coronary artery disease were studied. Patients were randomized into two matched groups. Group A received trimetazidine (20mg three times daily) for 2 months, while group B received a placebo during the same period. The usual antianginal medications were not altered during the study. At baseline and after 2 months, all patients underwent low-dose dobutamine echocardiography (5–20µg.kg–1.min–1), and a symptom-limited cardiopulmonary exercise test.
Results On initial evaluation, systolic wall thickening score index, heart rate, systolic blood pressure and rate pressure product were similar at rest and peak dobutamine in both groups. However, at 2 months, group A patients had significant improvements in the rest and peak systolic wall thickening score index (13% and 20·7%, P<0·001) and ejection fraction (19·7% and 14·1%, P<0·001) without concomitant changes in heart rate and blood pressure. Peak VO2was also significantly increased in patients taking trimetazidine (15%, P=0·001 vs controls).
Conclusions In patients with ischaemic cardiomyopathy, trimetazidine improves the contractile response of chronically dysfunctional myocardium to dobutamine without haemodynamic changes. This effect was associated with improvements in left ventricular function and peak VO2.
Key Words: Trimetazidine, dysfunctional myocardium, dobutamine-stress echocardiography, contractility
f1 Correspondence: Romualdo Belardinelli, MD, FESC, Azienda Ospedaliera "G.M.Lancisi", Ancona, Italy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Tuunanen, E. Engblom, A. Naum, K. Nagren, M. Scheinin, B. Hesse, K.E. Juhani Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, et al. Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy Circulation, September 16, 2008; 118(12): 1250 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Belardinelli, M. Solenghi, L. Volpe, and A. Purcaro Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect Eur. Heart J., May 1, 2007; 28(9): 1102 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Labinskyy, M. Bellomo, M. P. Chandler, M. E. Young, V. Lionetti, K. Qanud, F. Bigazzi, T. Sampietro, W. C. Stanley, and F. A. Recchia Chronic Activation of Peroxisome Proliferator-Activated Receptor-{alpha} with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, G. Calori, O. Alfieri, and A. Margonato A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure J. Am. Coll. Cardiol., September 5, 2006; 48(5): 992 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk Optimizing cardiac Fatty Acid and glucose metabolism as an approach to treating heart failure. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 228 - 230. [Abstract] [PDF]
|
|
|
|
|
|
G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J., April 2, 2006; 27(8): 942 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lee, R. Campbell, M. Scheuermann-Freestone, R. Taylor, P. Gunaruwan, L. Williams, H. Ashrafian, J. Horowitz, A. G. Fraser, K. Clarke, et al. Metabolic Modulation With Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment Circulation, November 22, 2005; 112(21): 3280 - 3288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and I. C. Okere Metabolic therapies for heart disease: Fish for prevention and treatment of cardiac failure? Cardiovasc Res, November 1, 2005; 68(2): 175 - 177. [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Di Napoli, A A Taccardi, and A Barsotti Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy Heart, February 1, 2005; 91(2): 161 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vitale, M. Wajngaten, B. Sposato, O. Gebara, P. Rossini, M. Fini, M. Volterrani, and G. M.C. Rosano Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease Eur. Heart J., October 2, 2004; 25(20): 1814 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. I.W. Galasko and A. Lahiri The non-invasive assessment of hibernating myocardium in ischaemic cardiomyopathy--a myriad of techniques Eur J Heart Fail, June 1, 2003; 5(3): 217 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.V. Cokkinos Can metabolic manipulation reverse myocardial dysfunction? Eur. Heart J., December 1, 2001; 22(23): 2138 - 2139. [PDF]
|
|